Search
Close this search box.

FDA LETTER TO PFIZER RAISES CONCERNS ABOUT SAFETY, EFFICACY OF ESTRING

<< INSERT BREADCRUMBS >>

FDA LETTER TO PFIZER RAISES CONCERNS ABOUT SAFETY, EFFICACY OF ESTRING


  • FDA LETTER TO PFIZER RAISES CONCERNS ABOUT SAFETY, EFFICACY OF ESTRING

FDA 06/19/2018’s letter to Pfizer about its direct-to-consumer video that “makes false or misleading claims and/or representations about the risks associated with and the efficacy of Estring.” The FDA further states in the letter that “This video is especially concerning from a public health perspective because it fails to include any risk information about Estring, which is a drug that bears a boxed warning due to several serious, life-threatening risks, including endometrial cancer, breast cancer, and cardiovascular disorders, as well as numerous contraindications and warnings.  The video thus creates a misleading impression about the safety and efficacy of Estring.”

Questions About This Article Or Topic?

Please Contact Us

Disclaimer

You understand that by using the internet or this form to communicate directly or indirectly with the firm or any individual member of the firm does not constitute or establish an attorney-client relationship. Please do not use this form to provide confidential or time-sensitive information to the firm.